ArriVent BioPharma (AVBP) currently reports a target price of $46. Use the charts on this page to explore ArriVent BioPharma's target price history and peer comparisons.

Analysts' average 12-month price target for ArriVent BioPharma is $46, about 61.0% upside from the current share price of $28.57. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $46, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for ArriVent BioPharma, and consider following AVBP for alerts when major investors trade the stock.